Welcome reception

Welcome & introduction
Gareth Morgan & Ola Landgren

Session 1: Genomics 2024
Chairs: Brian Walker & Leif Bergsagel

• An all-genetic classifier and AI based prognostic scores: Francesco Maura
• The genetic basis for racial disparity in MM: Kylee MacLachlan
• scATACseq of Waldenström macroglobulinaemia: Gareth Morgan
• NSD2 as a therapeutic target: Yubao Wang
• The t(4:14) and apoptosis: Lawrence Boise
• Epigenetic data from CoMMpass: Benjamin Barwick

Panel discussion

• Hyper APOBEC MM: Marios Papadimitriou
• The ncGenome in MM: Patrick Blaney
• Tumor suppressor gene inactivation in MM: Bachisio Ziccheddu
• Membrane markers as targets in the t(4:14): Arun Wiita
• Bringing genomics to the clinic: Sarah Gooding

Panel discussion: Using genomic targets in MM

Break

Session 2: Resistance mechanisms
Chairs: Francesco Maura & Niels Weinhold

• PHF19 a tudor domain protein and HRMM: Brian Walker
• Chr1q in the evolution to HR MM: Monika Chojnacka
• Mechanisms of resistance to bispecifics: Paola Neri
• Lenalidomide resistance: Charlotte Pawlyn
• Transcriptional resistance to IMiD: Leif Bergsagel
• Genomic profiling of treated SMM: Benjamin Diamond

Panel discussion: addressing drug resistance

Lunch

Session 3: Biological basis of therapy                                                               
Chairs: Charlotte Pawlyn & Felipe Prósper

• Treatment of high-risk myeloma: Robert Orlowski
• The Vk*MYC mouse model: Marta Chesi
• Pre-clinical models of MM: José Ángel Martínez-Climent
• Spatial transcriptomics: Niels Weinhold
• Epigenetic and microenvironment drivers of disease progression in MM: Felipe Prósper
• Microenvironment-mediated resistance to treatment: Madhav Dhodapkar

Panel discussion: future strategies for myeloma management

Break

Session 4: MMRF update session
Chairs: George Mulligan & Hearn Jay Cho

• MyDRUG trial – status and learnings: Noa Biran
• CoMMpass at 13 – the gift that keeps giving: Lawrence Boise
• Immune Atlas – insights and challenges: Manoj Bhasin
• MMRF clinical and translational research strategy: George Mulligan

 Panel discussion

Session 5: Clinical trial updates
Chairs: Marc Raab & Ola Landgren

• Moving clinical trials forward towards a cure: Saad Usmani
• Strategies for the clinical evaluation of bispecifics: Ola Landgren
• Belantamab mafodotin in the treatment of MM: Suzanne Trudel
• Isatuximab combinations for the treatment of MM: Thomas Martin
• The role of bisphosphonates in the context of combination therapies and deep response: Suzanne Lentzsch

Panel discussion: questions for clinical trials

Day 1 conclusions

Session 6:  Novel Targets Part 2
Chairs: Paola Neri & Faith Davies                                                                                

• Synergistic antitumor activity of alnuctamab and CELMoDs: Paula Rodríguez-Otero
• Oncogenic RAS mutations as drivers of MM: Ryan Young
• Targeting RAS with monobodies: Faith Davies
• Targeting plasma cell metabolism: Mala Shanmugam
• CL 131 (Iopofosine I-131) in RRMM: Sikander Ailawadhi

Panel discussion: developing novel targets for the clinic

Break

Session 7: Debates in MM
Chairs: Ola Landgren & David Avigan

1. We should risk stratify

For risk stratification: Saad Usmani         

For one size fits all: Gareth Morgan

2. Bi-specifics vs CAR-T

For bispecifics: Marc Raab

For CAR-T: David Avigan

3. Short vs long duration therapy with bispecifics

For long duration: Ola Landgren           

For short duration: Hermann Einsele            

Panel discussion

Session 8: T-Cell Engagers: data session
Chairs: Paula Otero & Hans Lee

• Innovative CAR-T designs and targets: Hermann Einsele
• GPRC5D TCE resistance mechanisms: Nizar Bahlis
• Elranatamab: Nizar Bahlis
• ADC in the MM context: Hans Lee
• CAR-T developments: Yi Lin
• Developing the use of bispecific antibodies: Paula Rodríguez-Otero
• Clinical management of CAR-T agents and their use in older adults: Ciara Freeman

Panel discussion: optimizing the use of bispecifics and CAR-T in the clinic

Summary & closing remarks